Needlefree nanopatch vaccines benefits and history. Engineered to directly deposit vaccine amongst dense population of key immune cells in the skin, developing an efficient and effective immune response. Queensland startup vaxxas heads to us after biotech giant. The world health organisations who battle against polio has a new weapon after joining forces with vaxxas, the biotechnology company responsible for developing revolutionary vaccine delivery. Vaxxas is working on a new, less invasive vaccine delivery technology that creates a more potent immune response. Investment in vaxxas winner at 2012 vaccine industry. Kendall is president of vaxxas pty ltd, which he formed to commercialize the nanopatch technology. Application of the nanopatch to the skin is designed to be pain free, rapidly delivering vaccine directly to the abundant. The nanopatch applicator and a large version of the patch. David hoey is the ceo and director of the vaxxas, a company working on enhancing the performance of existing and next generation vaccines through a novel vaccine delivery technology called nanopatch.
The technology produces a dry form of a vaccine which only uses a fraction. Uniquest to bring the technology to use for human vaccinations. Vaxxas research project aims to advance nextgeneration technology for polio vaccine delivery. Mrk exclusive, worldwide rights to develop and commercialize a vaccine using vaxxas needlefree nanopatch vaccine delivery technology. You can also find a variety of government programs on our funding opportunities page for a full list of all available federal grants visit. Vaxxas, a privately owned biotechnology company focused on enhancing the performance of vaccines, has initiated a research project to evaluate its nanopatch platform for the. Vaxxas nanopatch is the future of needlefree vaccine professor mark kendall, cofounder and director, vaxxas. The nanopatch is comprised of an ultrahigh density array of very short projections invisible to the naked eye that are coated with vaccine. Prof kendall and his team invented the nanopatch technology at the australian institute for bioengineering and nanotechnology, university of queensland. Brisbanebased vaxxas to evaluate, develop and commercialize vaxxas innovative nanopatch vaccine delivery platform. About vaxxas launched in 2011, australian startup vaxxas is looking to commercialize the companys novel vaccine delivery technology called the nanopatch.
Vaxxas is developing what its calling the nanopatch, a halfinch square. Nanopatch concept to vaccine delivery vaxxas is pioneering a nextgeneration vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological. Vaxxas competitors, revenue and employees owler company. The nanopatch technology has also been licensed to usbased. Nanopatch technology makes polio vaccination more feasible. The research and development under his future fellowship led to spinout company vaxxas.
Below are examples of current grant solicitations in the area of nanoscience and nanotechnology. The vaxxas nanopatch jet coating instrument, developed in collaboration with invetech, is an advanced technology platform to support needlefree dermal drug delivery research and product development. Vaxxas nanopatch jet coating instrument good design. Professor mark kendall, an inaugural arc future fellow who has also received support from the arc discovery projects scheme, developed nanopatch. Vaxxas is developing an advanced platform for needlefree vaccine delivery. Nanopatch is a small square of silicon that sticks on the skin like a postage stamp and delivers. Vaxxas is a venture capital funded technology startup company developing. Merck partnership accelerates needlefree vaccine delivery. The nanopatch technology also originated at the university of. The nanopatch approach consists of using thousands of vaccine coated microprojections that painlessly perforate into the outer layers of the skin. Vaccinations have historically been given using syringes and needles.
It uses thousands of vaccinecoated pins that perforate into the skin. We are extremely grateful to the who for providing funding to vaxxas pty ltd. Professor mark kendall, an inaugural arc future fellow at the university of queensland, is a pioneer in needlefree immunisation technology that promises to eliminate the need for needles and syringes for vaccine delivery. A fresh study of the nanopatch a microscopic vaccine delivery platform has. Nanopatch could revolutionize vaccine delivery mddi online. The grant was used to further develop the technology. The nanopatch jet coating instrument is one of a series of. Vaxxas ceo mr david hoey said the first human vaccination studies are scheduled for this year. Vaxxass strategy is to develop its own vaccine pipeline and license out the nanopatch technology to other drug developers. Vaxxass competitors, revenue, number of employees, funding and acquisitions. Vaxxas is disrupting and revolutionizing the way vaccines are delivered, through their innovative nanopatch. Queensland startup vaxxas is relocating to massachusetts after striking a major new deal with biotech giant merck, one of the largest vaccine firms in the world.
Dr stephen thompson, managing director of brandon capital partners, said launching vaxxas as a company was a. This funding creates an important inflection point for vaxxas, as we are. Additionally, some federal agencies have specific web pages for nanotechnology funding opportunities. Unlock charts on crunchbase charts can be found on various organization profiles and on hubs pages, based on data availability. Nanopatch administers vaccines painlessly national. A startup named vaxxas is one of a group of companies trying to get. Vaxxas nanopatch technology aims to provide an optimized, differentiated needlefree vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
Delivery of solutions to improve global health, vaccine development program. Securing secondround funding can turbocharge a young business virgin voyeur. Vaxxas was incorporated in 2011 and is based in brisbane, australia. An advanced platform that vaccinates by applying a patch to the skin for a few seconds. And apparently he has caught the attention of the right people, as in october 2012 pharma giant merck invested an undisclosed sum to help develop the nanopatch in return for certain future rights. Startup develops nanopatch for polio vaccine delivery digital journal.
Australian company vaxxas is pioneering a nextgeneration vaccine delivery platform called nanopatch, a microscopic patch that consists of an array of thousands of vaccine coated microprojections that perforate and deliver vaccine into the outer layers of the skin when applied with an applicator device. Conservative way with syringes and needles is oriented on muscle cells, but the nanopatch technology is oriented on skin cells. Nanopatchrevolutionising treatment of disease across the. The nanopatch technology, now being developed by privately held biotechnology company vaxxas, originated from vaxxas chief technology officer professor mark kendalls research group at uqs. Bioengineer developing needlefree nanopatch vaccines. The nanopatch is designed to place a tiny amount of vaccine just under the skin without the need for a needle jab. Nanopatch is the vaccine delivery system for people who. Leveraging both the potent immunogenic response and product thermostability of nanopatchenabled vaccines, vaxxas is applying its technology to improve the performance of vaccines, with initial applications targeting infectious disease and oncology. We are extremely grateful to the who for providing funding to vaxxas pty ltd, the biotechnology company commercialising the nanopatch.
Vaxxas is a medical technology startup located in brisbane, revolutionizing the way vaccines are delivered. Arc future fellow pioneers needlefree immunisation for the world. Delivery of solutions to improve global health, discovery and translational sciences, pneumonia program. Vaxxas initiates program with merck to optimize delivery. Uniquest led the initial commercialisation of the nanopatch technology prior to vaxxas being created. Application of the nanopatch to the skin is designed to be pain free, rapidly. Described in the australian media as a paradigm shift and gamechanging technology in the field of vaccination, the nanopatch has the potential to revolutionize the process of administering vaccines, making the process far easier, cheaper and much less intimidating for the many people who fear needles. A fresh study of the nanopatch a microscopic vaccine delivery platform.
The money will enable university of queenslands professor. Vaxxas and uq deliver needlefree nanopatch choose brisbane. Invetech and vaxxas named recipients of the 2015 good design award for development of nanopatch jet coating instrument for needlefree drug delivery. During 2012, vaxxas entered into a research partnership with merck and co, one of the major international players in the vaccine business. Nanopatch polio vaccine success uq news the university. Nanopatch for effective, painfree vaccine delivery. Instead of syringes, nanopatches for polio vaccination. Vaxxas research project aims to advance nextgeneration. The tips of nanopatchs microprojections, or microneedles, are coated with a vaccine material and release it directly to key immune cells immediately below the skins surface. Vaxxas nanopatch is the future of needlefree vaccine. Who says tech like nanopatch can help get vaccines to the people. In 2009 professor mark kendall received funding through the arc future. Vaxxas is a company working to improve current vaccines and create the next generation of immunizations. Invetech and vaxxas named recipients of the 2015 good.
Vaxxas initiates program with merck to optimize delivery of next generation vaccines utilizing novel mechanism for immune system activation the yates networkkathryn morris, 8456359828. Charles ross, head of clinical operations and supply at. Vaxxas secures funding for clinical trials of nanopatch delivered. According to vaxxas, not only is it needlefree, but this technology can save on money and promise greater safety. The company, a startup of the university of queenslands uniquest commercialisation company. Tri and vaxxas receive funding for australianfirst. Msd also agreed to provide funding to vaxxas to conduct research evaluating the potential of using vaxxas nanopatch platform for vaccine candidates. The vaxxas nanopatch promises needlefree vaccinations. Merck has announced that it has entered into a partnership with vaxxas to further develop technology to deliver vaccines without the need for needles. Vaxxas nanopatch technology enables vaccination by briefly applying a small patch to the skin, offering a safer, painless and easier to use alternative to needle delivery. Arc future fellow pioneers needlefree immunisation for.
Efforts to rid the world of polio have taken another significant step. Although clinical trials have begun, the vaxxas founder and chief technology officer acknowledged that actual use of the nanopatch was still. Merck to partner with vaxxas for needlefree vaccines. Efforts to rid the world of polio have taken another significant step, thanks to research led by university of queensland bioscience experts and funding. Nanopatch technology is being commercialised by vaxxas pty ltd, which has scaled the nanopatch from use in small models to prototypes for human use. Vaxxas nanopatch technology consists of an array of thousands of vaccinecoated microprojections that perforate into the outer layers of the skin. Needlefree vaccination and vaccine delivery solutions that safely and cost effectively amplify vaccine efficacy using nanopatch technology developed by. Needlefree vaccination and vaccine delivery solutions that safely and cost effectively amplify vaccine efficacy using nanopatch technology developed by vaxxas. Vaxxas, a developer of a novel vaccine delivery technology called nanopatch, has agreed a research partnership with merck. Professor kendall heads a team responsible for the development of the nanopatch, a breakthrough technology that is a bit like a postage stamp. The nextgeneration vaccine delivery system, created by vaxxas, is called the nanopatch and is the size of an adult thumbnail. Yes, there is sufficient amount of immune material because there is a huge difference between conservative way and the nanopatch way of presentation. Based on looks alone, the nanopatch lives up to its name. Brisbanebased company vaxxas will start its first human vaccination studies for the nanopatch this year vaxxas developed the needlefree nanopatch vaccine delivery system, which has just been successfully used to deliver an inactivated polio vaccine with the help of experts from the university of.